Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).
The relation of cardiac troponin-I (cTnI) to clinical outcomes was examined in patients with decompensated heart failure and concomitant acute coronary syndrome enrolled into the Randomized Intravenous TeZosentan 4 (RITZ-4) study. RITZ-4 was a multicenter, randomized, double-blind, placebo-controlled trial of the endothelin receptor antagonist tezosentan in patients admitted with acute heart failure and concomitant acute coronary syndrome. One hundred ninety-two patients were enrolled in this study. Patients with baseline cTnI values were included in this analysis, and the relation between cTnI and the composite clinical primary end point of RITZ-4 was evaluated.
Gattis
Wendy A
WA
Duke Clinical Research Institute, Duke University Medical Center, 2400 N. Pratt Street, Box 17969, Durham, NC 27710, USA. wendy.gattis@duke.edu
O'Connor
Christopher M
CM
Hasselblad
Vic
V
Adams
Kirkwood F
KF
Kobrin
Isaac
I
Gheorghiade
Mihai
M
D000208:Acute Disease; D000368:Aged; D003327:Coronary Disease / Q000097:blood* / Q000150:complications; D065128:Endothelin Receptor Antagonists; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000150:complications; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013777:Tetrazoles / Q000627:therapeutic use; D019210:Troponin I / Q000097:blood*; D014665:Vasodilator Agents / Q000627:therapeutic use
D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D013777:Tetrazoles; D019210:Troponin I; D014665:Vasodilator Agents; C120582:tezosentan